case_images: PMC10912635_01
case_images: PET/CT images in axial and coronal reconstruction. The target lesion is indicated by an arrow. FDG avidity is expressed by the Deauville score (DS). Before initiation of MEPED, DS: 4 (A, B). After 3 months of therapy, DS: 3 (C, D). After 9 months of therapy, DS: 3 (E, F). Two months after discontinuation of therapy, DS: 3 (G, H).
case_images: fphar-15-1334233-g001.jpg
case_images: PMC10912635_01_fphar-15-1334233-g001.jpg
case_images: F1
case_images: The next PET/CT in July 2023 continued to show CR (DS: 3) and no evidence of pneumonitis (PET/CT images illustrating the response are shown in Figure 1).
case_images: Therapy timeline. Schematic portrayal of the different therapy regimens in chronological order. BEACOPP = bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone. BV = brentuximab vedotin. Pem = pembrolizumab. MEPED = treosulfan, everolimus, pioglitazone, etoricoxib, dexamethasone.
case_images: fphar-15-1334233-g002.jpg
case_images: PMC10912635_01_fphar-15-1334233-g002.jpg
case_images: F2
case_images: The different therapy regimens in chronological order are shown in Figure 2.